AuntMinnie

NOVEMBER 1, 2024

Centers for Medicare and Medicaid Services (CMS) has released its final rule for the 2025 Medicare Physician Fee Schedule (MPFS), which includes coverage of colorectal cancer screening with CT colonography (CTC) for the first time. In the end, this translates to a finalized 2025 MPFS conversion factor of $32.35, a decrease of 2.8%

Radiopharmaceuticals 85

Radiopharmaceuticals Medicare Computed Tomography Hospital 85

AuntMinnie

OCTOBER 14, 2024

These SSTRs can be targeted both with gallium-68 (Ga-68) imaging agents and therapeutic lutetium-177 (Lu-177) radiopharmaceuticals using a so-called theranostics approach. Meningiomas are the most common primary adult intracranial tumors and most meningiomas show high expression of somatostatin receptors (SSTRs). In the U.S.,

Nuclear Medicine 110

Nuclear Medicine Radiopharmaceuticals Insurance Clinic 110

Imaging Technology

JANUARY 5, 2024

milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Nuclear Medicine Pharmaceutical 52

AuntMinnie

NOVEMBER 4, 2024

Centers for Medicare & Medicaid Services (CMS) 2025 Medicare Physician Fee Schedule (MPFS) and Hospital Outpatient Prospective Payment System (HOPPS) final rules. Although the 2025 MPFS calls for an overall 2.9% The change to the MPFS conversion factor reflects the 0% update required by statute for 2025, the expiration of the 2.9%

Radiation Oncology 80

Radiation Oncology Nuclear Medicine Medicare Imaging 80

Imaging Technology

JULY 5, 2024

Lantheus intends to begin a Phase 1/2a study with 177Lu-DOTA-RM2 in prostate cancer patients in 2025. mtaschetta-millane Fri, 07/05/2024 - 06:00 July 5, 2024 — Lantheus Holdings, Inc. , 68Ga-DOTA-RM2 will be used as a companion diagnostic.

Diagnostic 105

Diagnostic Radiopharmaceuticals Disease IT 105

Imaging Technology

NOVEMBER 1, 2024

Based on the advantageous results for absolute tumor and normal organ uptake seen in Phase 1, the Phase 2 study will explore the following concepts: Administration of a significantly higher overall injected radioactivity in comparison to recent Phase 3 clinical trials of other agents. Front loading of administered radioactivity.

Nuclear Medicine 52

Nuclear Medicine Radiation Radiopharmaceuticals Clinic 52

Imaging Technology

APRIL 3, 2023

Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.

Medical 98

Medical Radiopharmaceuticals Pharmaceutical Radiation 98